Related references
Note: Only part of the references are listed.Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
Emanuela Ferraro et al.
NPJ BREAST CANCER (2022)
The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
Xinwei Wang et al.
FRONTIERS IN ONCOLOGY (2022)
Current and Future Management of HER2-Positive Metastatic Breast Cancer
Olga Martinez-Saez et al.
JCO ONCOLOGY PRACTICE (2021)
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Neil T. Conlon et al.
BRITISH JOURNAL OF CANCER (2021)
The Exciting New Field of HER2-Low Breast Cancer Treatment
Daniel Eiger et al.
CANCERS (2021)
Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
Alejandro Garcia-Alvarez et al.
CANCERS (2021)
Breast Cancer, Version 4.2021 Featured Updates to the NCCN Guidelines
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
F. Montemurro et al.
ANNALS OF ONCOLOGY (2020)
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
Qiao Li et al.
CLINICAL CANCER RESEARCH (2019)
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
Denis M. Collins et al.
CANCERS (2019)
Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
Fei Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database
Kejia Hu et al.
BREAST CANCER (2019)
HER2-positive breast cancer: Current and new therapeutic strategies
Santiago Escriva-de-Romani et al.
BREAST (2018)
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary
Sharon H. Giordano et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Rupert Bartsch et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2018)
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
Xin Li et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Fei Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Brain Metastases in Newly Diagnosed Breast Cancer A Population-Based Study
Allison M. Martin et al.
JAMA ONCOLOGY (2017)
Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry
Yunting Zhu et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2016)
Treatment and survival patterns of Chinese patients diagnosed with breast cancer between 2005 and 2009 in Southwest China: An observational, population-based cohort study
Zuxiang Peng et al.
MEDICINE (2016)
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
Arlene Chan
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study
M. Kreuter et al.
ANNALS OF ONCOLOGY (2013)
Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era
Erin M. Olson et al.
BREAST (2013)
Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US
Kathleen A. Cronin et al.
CANCER INVESTIGATION (2010)
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases
Brian Leyland-Jones
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer
Zsolt Gabos et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
